Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab DDI Study in Psoriasis
NCT03718884Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirikizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration (Cmax) of Midazolam at Day 116, Maximum Observed Drug Concentration (Cmax) of Warfarin at Day 116 and 8 more. Started Oct 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03718884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718884.